Literature DB >> 20870944

Molecular intercommunication between the complement and coagulation systems.

Umme Amara1, Michael A Flierl, Daniel Rittirsch, Andreas Klos, Hui Chen, Barbara Acker, Uwe B Brückner, Bo Nilsson, Florian Gebhard, John D Lambris, Markus Huber-Lang.   

Abstract

The complement system as well as the coagulation system has fundamental clinical implications in the context of life-threatening tissue injury and inflammation. Associations between both cascades have been proposed, but the precise molecular mechanisms remain unknown. The current study reports multiple links for various factors of the coagulation and fibrinolysis cascades with the central complement components C3 and C5 in vitro and ex vivo. Thrombin, human coagulation factors (F) XIa, Xa, and IXa, and plasmin were all found to effectively cleave C3 and C5. Mass spectrometric analyses identified the cleavage products as C3a and C5a, displaying identical molecular weights as the native anaphylatoxins C3a and C5a. Cleavage products also exhibited robust chemoattraction of human mast cells and neutrophils, respectively. Enzymatic activity for C3 cleavage by the investigated clotting and fibrinolysis factors is defined in the following order: FXa > plasmin > thrombin > FIXa > FXIa > control. Furthermore, FXa-induced cleavage of C3 was significantly suppressed in the presence of the selective FXa inhibitors fondaparinux and enoxaparin in a concentration-dependent manner. Addition of FXa to human serum or plasma activated complement ex vivo, represented by the generation of C3a, C5a, and the terminal complement complex, and decreased complement hemolytic serum activity that defines exact serum concentration that results in complement-mediated lysis of 50% of sensitized sheep erythrocytes. Furthermore, in plasma from patients with multiple injuries (n = 12), a very early appearance and correlation of coagulation (thrombin-antithrombin complexes) and the complement activation product C5a was found. The present data suggest that coagulation/fibrinolysis proteases may act as natural C3 and C5 convertases, generating biologically active anaphylatoxins, linking both cascades via multiple direct interactions in terms of a complex serine protease system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20870944      PMCID: PMC3123139          DOI: 10.4049/jimmunol.0903678

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

Review 1.  A cell-based model of hemostasis.

Authors:  M Hoffman; D M Monroe
Journal:  Thromb Haemost       Date:  2001-06       Impact factor: 5.249

Review 2.  Structure and biology of complement protein C3, a connecting link between innate and acquired immunity.

Authors:  A Sahu; J D Lambris
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

Review 3.  Evolution of enzyme cascades from embryonic development to blood coagulation.

Authors:  Maxwell M Krem; Enrico Di Cera
Journal:  Trends Biochem Sci       Date:  2002-02       Impact factor: 13.807

4.  Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury.

Authors:  E A Lidington; D O Haskard; J C Mason
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

5.  Distal recognition site for classical pathway convertase located in the C345C/netrin module of complement component C5.

Authors:  A Sandoval; R Ai; J M Ostresh; R T Ogata
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

6.  Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis.

Authors:  Ines J Laudes; Jeffrey C Chu; Sujata Sikranth; Markus Huber-Lang; Ren-Feng Guo; Niels Riedemann; J Vidya Sarma; Alvin H Schmaier; Peter A Ward
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 7.  Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

Authors:  M C Poon; R d'Oiron; I Hann; C Négrier; L de Lumley; A Thomas; A Karafoulidou; C Demers; A Street; A Huth-Kühne; P Petrini; E Fressinaud; M Morfini; L Tengborn; A Marquès-Verdier; R Musso; O Devecioglu; D S Houston; S Lethagen; C Van Geet; M von Depka; C Berger; P Beurrier; H A Britton; W Gerrits; C Guthner; S Kuhle; J J Lorenzo; P E Makris; N Nohe; P Paugy; B Pautard; M F Torchet; N Trillot; M Vicariot; J Wilde; M Winter; H Chambost; J Ingerslev; M Peters; G Strauss
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

Review 8.  Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.

Authors:  L Bajzar
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-12       Impact factor: 8.311

Review 9.  Role of inflammatory mediators in thrombogenesis.

Authors:  Ronald J Shebuski; Kenneth S Kilgore
Journal:  J Pharmacol Exp Ther       Date:  2002-03       Impact factor: 4.030

10.  Factor Xa activates endothelial cells by a receptor cascade between EPR-1 and PAR-2.

Authors:  F Bono; P Schaeffer; J P Hérault; C Michaux; A L Nestor; J C Guillemot; J M Herbert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

View more
  246 in total

1.  Early complementopathy after multiple injuries in humans.

Authors:  Anne-Maud Burk; Myriam Martin; Michael A Flierl; Daniel Rittirsch; Matthias Helm; Lorenz Lampl; Uwe Bruckner; Gregory L Stahl; Anna M Blom; Mario Perl; Florian Gebhard; Markus Huber-Lang
Journal:  Shock       Date:  2012-04       Impact factor: 3.454

2.  Plasminogen is a complement inhibitor.

Authors:  Diana Barthel; Susann Schindler; Peter F Zipfel
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

Review 3.  The role of complement in the early immune response to transplantation.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 4.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

5.  A metalloproteinase karilysin present in the majority of Tannerella forsythia isolates inhibits all pathways of the complement system.

Authors:  Monika Jusko; Jan Potempa; Abdulkarim Y Karim; Miroslaw Ksiazek; Kristian Riesbeck; Peter Garred; Sigrun Eick; Anna M Blom
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 6.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

Review 7.  Mast Cells and Wound Healing.

Authors:  Carole A Oskeritzian
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-02       Impact factor: 4.730

8.  Soluble membrane attack complex is diagnostic for intraventricular shunt infection in children.

Authors:  Theresa N Ramos; Anastasia A Arynchyna; Tessa E Blackburn; Scott R Barnum; James M Johnston
Journal:  JCI Insight       Date:  2016-07-07

9.  Complement mediates a primed inflammatory response after traumatic lung injury.

Authors:  J Jason Hoth; Jonathan D Wells; Sarah E Jones; Barbara K Yoza; Charles E McCall
Journal:  J Trauma Acute Care Surg       Date:  2014-03       Impact factor: 3.313

10.  Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model.

Authors:  Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.